<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026281</url>
  </required_header>
  <id_info>
    <org_study_id>AOI 2020 TEISSANDIER</org_study_id>
    <secondary_id>2020-A03240-39</secondary_id>
    <nct_id>NCT05026281</nct_id>
  </id_info>
  <brief_title>Bleeding Oral Anticoagulant Analyzer (BOA)</brief_title>
  <acronym>BOA</acronym>
  <official_title>Intérêt de l'Utilisation du &quot;Quantra® Haemostasis Analyser&quot; Lors de la Prise en Charge Des Patients présentant Une hémorragie Grave Sous Anticoagulant Oral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The quality of the reversion of these serious hemorrhagic accidents under oral anticoagulants&#xD;
      depends on the adequate use of reversion products but also on the speed of obtaining&#xD;
      hemostasis data allowing to evaluate the effectiveness of this &quot;chemical&quot; hemostasis. .&#xD;
&#xD;
      Clot formation can be studied using different visco-elastic methodologies&#xD;
      (thromboelastography or thromboelastometry) with a detectable change in clot formation with&#xD;
      oral anticoagulants.&#xD;
&#xD;
      These techniques have been proven in patients who are often unstable and present with severe&#xD;
      trauma with hemorrhagic shock, thus making it possible to guide the transfusion protocol.&#xD;
      However, the level of recommendations in these patients, who are often polyhydrated and&#xD;
      poly-transfused, is grade 1c due to small-scale studies with difficulty in analyzing the&#xD;
      values of the visco-elasticity parameters in these patients. In addition, these methods are&#xD;
      little used in current practice because of their difficult reading.&#xD;
&#xD;
      The use of visco-elastic methods in patients on oral anticoagulants has been little studied.&#xD;
      However, taking an oral anticoagulant mainly causes coagulation disorders. The use of these&#xD;
      methods would make it possible to assess the impact of the anticoagulant on hemostasis and to&#xD;
      verify the correct reversion of hemostasis parameters. Quantra®, one of the visco-elastic&#xD;
      methods, would make it possible to speed up the evaluation in the context of biology&#xD;
      relocated to the patient's bed with a simplified reading of the factors involved in the&#xD;
      formation of the clot in order to allow an immediate evaluation the quality of the reversion&#xD;
      performed which may have an impact on the re-administration of reversion products or even an&#xD;
      adaptation of the dose of reversion products according to the initial parameters at the time&#xD;
      of severe bleeding before reversion. The objective of this pilot study is to study the&#xD;
      metrological evolution, before and after reversion, of the hemostasis parameters evaluated by&#xD;
      the Quantra® system from HemoSonics in a patient being his own control in the context of a&#xD;
      severe hemorrhage occurring on oral anticoagulants (VKA or DOA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, prospective, cohort pilot study of physiopathology and physio-pharmacology,&#xD;
      testing the added value of innovative functional exploration in addition to routine&#xD;
      monitoring, in patients eligible for urgent reversion from anticoagulant therapy.&#xD;
&#xD;
      This study is part of the patient's routine care without modifying his management. In fact,&#xD;
      eligible patients with severe bleeding under oral anticoagulant therapy will be treated&#xD;
      according to departmental habits. The study will only consist of the addition of the analysis&#xD;
      of a blood sample using the Quantra® before and after reversion without modification of the&#xD;
      management.&#xD;
&#xD;
      All patients will be followed for the duration of hospitalization.&#xD;
&#xD;
      Primary objective :&#xD;
&#xD;
      The objective of this pilot study is to study the behavior of viscoelastic hemostasis&#xD;
      parameters assessed by the Quantra® System in the context of severe bleeding occurring under&#xD;
      oral anticoagulants (VKA or DOA).&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
      To study the effect of reversion of oral anticoagulants on hemostasis parameters assessed by&#xD;
      the Quantra® system in the context of severe bleeding.&#xD;
&#xD;
      To study, in the context of severe bleeding, the relationship between the hemostasis&#xD;
      parameters assessed by the Quantra® system and:&#xD;
&#xD;
        -  conventional hemostasis parameters,&#xD;
&#xD;
        -  the severity of the bleeding events before reversion, in the context of severe bleeding,&#xD;
&#xD;
        -  recurrent bleeding or thrombotic events occurring during hospitalization.&#xD;
&#xD;
      The primary endpoint will be all of the Quantra® parameter values measured during the&#xD;
      patient's therapeutic monitoring (before and after) without prioritization. The parameters of&#xD;
      Quantra® are:&#xD;
&#xD;
        -  CT: Clotting time (in seconds)&#xD;
&#xD;
        -  CTH: Clotting time with Heparinase (in seconds)&#xD;
&#xD;
        -  CTR: CT / CTH ratio clotting time&#xD;
&#xD;
        -  CS: overall stiffness of the clot (hPa)&#xD;
&#xD;
        -  PCS: Contribution of platelets to clot stiffness (hPa) FCS: Contribution of fibrinogen&#xD;
           to clot stiffness (hPa)&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Classic coagulation tests: (TP / INR), TCA, Fibrinogen, FII, FV, FVII, FX&#xD;
&#xD;
        -  Drug concentration (for DOA) by dilute thrombin time or specific anti-Xa activity&#xD;
&#xD;
        -  Type and volume of filling solutes before reversion&#xD;
&#xD;
        -  Assessment of blood loss (Hb, size of the hematoma)&#xD;
&#xD;
        -  Clinical outcome of reversion: haemostatic efficacy rate at 24 hours, occurrence of&#xD;
           haemorrhagic or thrombotic recurrences during hospitalization&#xD;
&#xD;
        -  Duration of hospitalization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>H0 : blood analyse with Quantra® H0+30 min : blood analyse with Quantra® D0+30 : end of study</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in viscoelastic hemostasis parameters assessed by the Quantra® system in the context of severe bleeding occurring under oral anticoagulants (VKA or DOA)</measure>
    <time_frame>Hour 0 and Hour 0+30min</time_frame>
    <description>Quantra® parameters were measured during the patient's therapeutic monitoring (before and after) without prioritization. The parameters of Quantra® are:&#xD;
CT / CTH ratio clotting time overall stiffness of the clot (hPa) Contribution of platelets to clot stiffness (hPa) Contribution of fibrinogen to clot stiffness (hPa)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in viscoelastic hemostasis parameters assessed by the Quantra® system in the context of severe bleeding occurring under oral anticoagulants (VKA or DOA)</measure>
    <time_frame>Hour 0 and Hour 0+30min</time_frame>
    <description>Quantra® parameters were measured during the patient's therapeutic monitoring (before and after) without prioritization. The parameters of Quantra® are:&#xD;
CT : clotting time (in seconds) CTH clotting time with heparinase (in seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in activated partial thromboplastin time (APTT) measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in prothrombin time test values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>changes in levels of fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in Factor II assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in Factor V assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in Factor VII assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in Factor X assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-factor Xa activity measurement</measure>
    <time_frame>Hour 0; Hour 0+30min; Hour 0+6 hours</time_frame>
    <description>change in anti-factor Xa activity measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of filling solutes before reversion</measure>
    <time_frame>Hour 0</time_frame>
    <description>Type of filling solutes before reversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of filling solutes before reversion</measure>
    <time_frame>Hour 0</time_frame>
    <description>Volume of filling solutes before reversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of blood loss</measure>
    <time_frame>Hour 0</time_frame>
    <description>haemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of blood loss</measure>
    <time_frame>Hour 0</time_frame>
    <description>haematoma size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical haemostasis evolution</measure>
    <time_frame>Hour 0+24</time_frame>
    <description>haematoma volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical haemostasis evolution</measure>
    <time_frame>Hour 0+24</time_frame>
    <description>Haematoma pain on numeric scale (0-10 points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical issue of reversion</measure>
    <time_frame>Hour 0+24</time_frame>
    <description>efficacy haemostatic rate at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical issue of reversion</measure>
    <time_frame>Hour 0+24</time_frame>
    <description>Recurrence of bleeding during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>at the end of hospitalization</time_frame>
    <description>how many days the patient is hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phone call</measure>
    <time_frame>Month 0+1</time_frame>
    <description>report of any adverse event occured in the month after the end of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>at H0 and H0+30min = blood sample taken</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quantra analyzer</intervention_name>
    <description>one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patient, male or female, treated long term with an oral anticoagulant&#xD;
             (anti-vitamin K or direct), admitted to a hospital emergency department for&#xD;
             intracerebral, digestive or intramuscular hemorrhage, defined as major according to&#xD;
             the criteria of the International Society of Thrombosis and Haemostasis1. These three&#xD;
             sites of bleeding are the most common.&#xD;
&#xD;
          2. Capable of giving informed consent to participate in research or in the event of&#xD;
             emergency care for a reference person.&#xD;
&#xD;
          3. Affiliated with a Social Security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incapable major.&#xD;
&#xD;
          2. Administration within the last 24 hours of parenteral anticoagulant.&#xD;
&#xD;
          3. Refusal of participation.&#xD;
&#xD;
          4. Pregnant or breast feeding mother&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorian Teissandier</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>+33473754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemorrhage</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Emergency</keyword>
  <keyword>Quantra analyzer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

